Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06646276 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
A Phase 3 study of Extensive-stage Small-cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT06646276 is a Phase 3 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 530 participants, above the 154-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (244% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT06646276, a Phase 3 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- BIOLOGICAL Atezolizumab
- DRUG Etoposide
- BIOLOGICAL BMS-986489 (BMS-986012+Nivolumab)
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Mid Florida Hematology and Oncology Center - Orange City
- Florida Cancer Specialists - North - St. Petersburg
North Dakota
- Local Institution - 0232 - Bismarck
- Local Institution - 0010 - Fargo
Texas
- Texas Oncology - Central/South Texas - Austin
- Texas Oncology - Northeast Texas - Tyler
Washington
- Swedish Cancer Institute - Edmonds - Edmonds
- Swedish Medical Center - Seattle
Alabama
- Southern Cancer Center, PC - Daphne
Arkansas
- Local Institution - 0283 - Hot Springs
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
Illinois
- Illinois Cancer Care - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2031-09-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06646276
The ClinicalTrials.gov registry entry for NCT06646276 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 154-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (244% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT06646276 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, North Dakota, Texas.
Frequently Asked Questions
What is clinical trial NCT06646276 about?
NCT06646276 is a clinical study titled "A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).". The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Ce...
What is the current status of trial NCT06646276?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2025-02-25. Estimated completion is 2031-09-05.
What conditions does trial NCT06646276 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT06646276?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (BIOLOGICAL), Etoposide (DRUG), BMS-986489 (BMS-986012+Nivolumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06646276?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06646276 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.